These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 18795273)

  • 1. High serum concentrations of cyclosporin related to administration of tigecycline.
    Stumpf AN; Schmidt C; Hiddemann W; Gerbitz A
    Eur J Clin Pharmacol; 2009 Jan; 65(1):101-3. PubMed ID: 18795273
    [No Abstract]   [Full Text] [Related]  

  • 2. Tigecycline and cyclosporine interaction-an interesting case of biliary-excreted drug enhancing the oral bioavailability of cyclosporine.
    Srinivas NR
    Eur J Clin Pharmacol; 2009 May; 65(5):543-4. PubMed ID: 19224202
    [No Abstract]   [Full Text] [Related]  

  • 3. Successful treatment with tigecycline of two patients with complicated urinary tract infections caused by extended-spectrum beta-lactamase-producing Escherichia coli.
    Geerlings SE; van Donselaar-van der Pant KA; Keur I
    J Antimicrob Chemother; 2010 Sep; 65(9):2048-9. PubMed ID: 20554566
    [No Abstract]   [Full Text] [Related]  

  • 4. Altered bioavailability of tacrolimus following intravenous administration of tigecycline.
    Pavan M; Chaudhari AP; Ranganth R
    Am J Kidney Dis; 2011 Feb; 57(2):354. PubMed ID: 21251548
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment with tigecycline of recurrent urosepsis caused by extended-spectrum-beta-lactamase-producing Escherichia coli.
    Krueger WA; Kempf VA; Peiffer M; Nagele U; Unertl KE; Schroeder TH
    J Clin Microbiol; 2008 Feb; 46(2):817-20. PubMed ID: 18077630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tigecycline treatment for urinary tract infections: case report and literature review.
    Drekonja DM; Johnson JR
    J Chemother; 2011 Jun; 23(3):168-70. PubMed ID: 21742587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Favourable outcome in the treatment of carbapenem-resistant Enterobacteriaceae urinary tract infection with high-dose tigecycline.
    Brust K; Evans A; Plemmons R
    J Antimicrob Chemother; 2014 Oct; 69(10):2875-6. PubMed ID: 24879666
    [No Abstract]   [Full Text] [Related]  

  • 8. Treatment of recurrent urosepsis with tigecycline: a pharmacological perspective.
    Curcio D
    J Clin Microbiol; 2008 May; 46(5):1892-3. PubMed ID: 18460636
    [No Abstract]   [Full Text] [Related]  

  • 9. Cyclosporine lymphocyte level and lymphocyte count: new guidelines for tailoring immunosuppressive therapy.
    Barbari A; Stephan A; Masri M; Mourad N; Kamel G; Kilani H; Karam A; Daya IA
    Transplant Proc; 2003 Nov; 35(7):2742-4. PubMed ID: 14612101
    [No Abstract]   [Full Text] [Related]  

  • 10. Should tigecycline be considered for urinary tract infections? A pharmacokinetic re-evaluation.
    Nix DE; Matthias KR
    J Antimicrob Chemother; 2010 Jun; 65(6):1311-2. PubMed ID: 20378673
    [No Abstract]   [Full Text] [Related]  

  • 11. Neoral (cyclosporine) C2 monitoring in renal transplant recipients: a single-center experience in Asia.
    Wong HS; Morad Z
    Transplant Proc; 2003 Feb; 35(1):230-1. PubMed ID: 12591376
    [No Abstract]   [Full Text] [Related]  

  • 12. Beware of drug interaction between tigecycline and tacrolimus.
    Chow KM; Pang WF; Chan GCK; Leung CB; Szeto CC; Li PKT
    Nephrology (Carlton); 2020 Jan; 25(1):99-100. PubMed ID: 31099103
    [No Abstract]   [Full Text] [Related]  

  • 13. Optimization of cyclosporine therapy with abbreviated area under the curve method in renal transplant.
    Yang WC; Chen YF; King KL; Wu TH; Chen Hsu RY ; Tang JJ; Loong CC; Chou MH; Lin MF; Lui WY
    Transplant Proc; 2000 Nov; 32(7):1685-7. PubMed ID: 11119892
    [No Abstract]   [Full Text] [Related]  

  • 14. High performance liquid chromatography cyclosporine monitoring: a predictor of renal graft outcome.
    Cicciarelli J; Avila D; Iwaki Y; Sather H; Mendez R
    Transplant Proc; 1998 Aug; 30(5):1683-4. PubMed ID: 9723243
    [No Abstract]   [Full Text] [Related]  

  • 15. Is the lower cyclosporine concentration at 2 hours after dosing safe in kidney transplant recipients?
    Einollahi B; Rostami Z; Kalantar E; Lessan-Pezeshki M; Pourfarziani V; Nemati E
    Transplant Proc; 2011 Mar; 43(2):488-90. PubMed ID: 21440741
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abbreviated cyclosporine pharmacokinetic profiling in clinical renal transplantation: from principles to practice.
    Vathsala A; Lu YM
    Transplant Proc; 2001; 33(7-8):3137-9. PubMed ID: 11750348
    [No Abstract]   [Full Text] [Related]  

  • 17. Tigecycline in treatment of multidrug-resistant Gram-negative bacillus urinary tract infections: a systematic review.
    Brust K; Evans A; Plemmons R
    J Antimicrob Chemother; 2014 Oct; 69(10):2606-10. PubMed ID: 24879669
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical validation studies of Neoral C(2) monitoring: a review.
    Nashan B; Cole E; Levy G; Thervet E
    Transplantation; 2002 May; 73(9 Suppl):S3-11. PubMed ID: 12023607
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus.
    Oellerich M; Armstrong VW; Schütz E; Shaw LM
    Clin Biochem; 1998 Jul; 31(5):309-16. PubMed ID: 9721427
    [No Abstract]   [Full Text] [Related]  

  • 20. Optimization of cyclosporine therapy in kidney transplantation.
    Remuzzi G; Perico N; Gaspari F
    Transplant Proc; 1998 Aug; 30(5):1673-6. PubMed ID: 9723238
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.